ALK inhibitors for clinical use in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in various solid and hematological tumors.
• Crizotinib, an ALK and c-Met inhibitor, has shown efficacy in ALK-positive non-small-cell lung cancer and other malignancies with a favorable toxicity profile.

Purpose of the Study:

• To review the clinical applications of anaplastic lymphoma kinase (ALK) inhibitors in ALK-positive tumors.
• To discuss the mechanisms of resistance that develop against ALK inhibitors.

Main Methods:

• Literature review of clinical studies and preclinical research on ALK inhibitors.
• Analysis of treatment outcomes and resistance patterns in patients with ALK-positive cancers.

Main Results:

• Anaplastic lymphoma kinase (ALK) inhibitors represent a significant advancement in personalized cancer therapy.
• Development of resistance to ALK inhibitors is a critical clinical challenge that requires further investigation.

Conclusions:

• ALK inhibitors offer effective therapeutic options for specific cancer types.
• Understanding and overcoming resistance mechanisms are essential for improving long-term patient outcomes.